Takeda’s Hyqvia secures US FDA approval to treat adults with CIDP
The US FDA has approved Hyqvia as a maintenance therapy to inhibit the relapse of neuromuscular disability and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Jan 24
The US FDA has approved Hyqvia as a maintenance therapy to inhibit the relapse of neuromuscular disability and…
17 Jan 24
Previously known as CTX-001, Casgevy is a non-viral ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with…
17 Jan 24
The approval was based on results from the Phase IB/III IMscin001 study which showed the SC formulation showed…
12 Jan 24
Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments,…
11 Jan 24
CDD-2107 is made using effective components of Chinese herbal medicine, Chaenomelis Fructus, to treat myofibrillar myopathy and has…
11 Jan 24
The approval was based on positive data from a Phase 3 trial in which patients who received Nucala…
11 Jan 24
EC has cleared Adagrasib as a targeted treatment option for adult patients with KRASG12C-mutated advanced NSCLC and disease…
10 Jan 24
The collaboration leverages NovaBay's extensive expertise in eye care, demonstrated by its Avenova brand, and Sonoma's ability to…
10 Jan 24
AbbVie has launched the solution to treat PD with severe motor fluctuations and hyperkinesia or dyskinesia, and when…
10 Jan 24
Under the agreement, Menarini will buy the exclusive rights to commercialise cefepime-taniborbactam in 96 countries in return for…